Consensus Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
12.88 ^USD	+1.42%		-11.78%	-40.86%

Apr. 16	Foghorn Therapeutics Names Kristian Humer CFO	MT
Mar. 21	B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	MT

Evolution of the average Target Price on Viridian Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

edf6888d1be6388313ba0b85fd.Weq45ioLgOczj7qoafDkZuDqKd1V2dYNPP6YqbsHt10.N6X_lXw407ZZw_yYXLvRDI3ffaQZ7JVEDpPA7Mp2wS8sqe6yY2bf3gTMyQ~ab3155cc0fefdab4f2c67dd1a96f5bae

Analyst Recommendations on Viridian Therapeutics, Inc.

B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	Mar. 21	MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating	Feb. 28	MT
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating	Jan. 22	MT
Oppenheimer Raises Viridian Therapeutics Price Target to $36 From $35, Maintains Outperform Rating	Dec. 19	MT
Wedbush Raises Viridian Therapeutics' PT to $40 From $37, Keeps Outperform Rating; Says Remains Among a Top Pick Into 2024	Dec. 19	MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $38 From $42, Maintains Market Outperform Rating	Nov. 14	MT
B. Riley Lowers Viridian Therapeutics' PT to $29 From $46 to Reflect Dilutive Financing, Lower Peak Sales in TED; Maintains Buy Rating	Nov. 14	MT
RBC Cuts Price Target on Viridian Therapeutics to $35 From $44, Keeps Outperform Rating, Speculative Risk Qualifier	23-10-31	MT
Wedbush Lowers Viridian Therapeutics' PT to $37 From $46 on Heels of Leadership Changes, Private Placement; Keeps Outperform Rating	23-10-31	MT
HC Wainwright Adjusts Price Target on Viridian Therapeutics to $37 From $40, Keeps Buy Rating	23-08-10	MT
Needham Adjusts Price Target on Viridian Therapeutics to $40 From $47, Keeps Buy Rating	23-08-10	MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $35 From $40, Maintains Outperform Rating	23-08-09	MT
Wells Fargo Adjusts Price Target on Viridian Therapeutics to $39 From $46, Maintains Overweight Rating	23-08-09	MT
Wedbush Lifts Viridian Therapeutics' PT to $46 From $45 After Adjusting Share Count Assumptions, Keeps Outperform Rating	23-08-09	MT
Wedbush Adjusts Viridian Therapeutics' PT to $45 From $48 After Reporting Results For Phase 1/2 Trial for Chronic Thyroid Eye Disease Treatment, Keeps Outperform Rating	23-07-11	MT
BTIG Research Initiates Coverage on Viridian Therapeutics With Buy Rating, $46 Price Target	23-06-14	MT
RBC Initiates Viridian Therapeutics at Outperform With Speculative Risk, Sets Price Target at $44, Sees 'Best Second-Mover Advantage' in Thyroid Eye Disease	23-05-30	MT
JMP Securities Adjusts Price Target on Viridian Therapeutics to $44 From $46, Maintains Market Outperform Rating	23-05-10	MT
Oppenheimer Adjusts Viridian Therapeutics Price Target to $40 From $45, Maintains Outperform Rating	23-05-10	MT
Wedbush Lifts Viridian Therapeutics' Price Target to $48 From $46, Keeps Outperform Rating	23-05-10	MT
Viridian Therapeutics Shares Rise After Wells Fargo Initiates Coverage at Overweight	23-04-17	MT
Wells Fargo Initiates Viridian Therapeutics at Overweight With $46 Price Target	23-04-17	MT
Stifel Starts Viridian Therapeutics at Buy With $49 Price Target	23-03-30	MT
HC Wainwright Adjusts Price Target on Viridian Therapeutics to $40 From $35, Maintains Buy Rating	23-03-09	MT
Wedbush Adjusts Price Target on Viridian Therapeutics to $46 From $43, Maintains Outperform Rating	23-03-08	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.7 USD

Average target price

39.36 USD

Spread / Average Target

+209.90%

High Price Target

46 USD

Spread / Highest target

+262.20%

Low Price Target

30 USD

Spread / Lowest Target

+136.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Viridian Therapeutics, Inc.

B. Riley
Wedbush
Oppenheimer
JMP Securities
RBC Capital Markets
HC Wainwright
Needham & Co.
Wells Fargo Securities
BTIG
Stifel Nicolaus
SVB Securities LLC
Credit Suisse
Evercore ISI
SVB Leerink
Ladenburg Thalmann

Ratings for Viridian Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar